Source: Virtual Congress 2021 – Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease?



Rating:

Share or cite this content

Citations should be made in the following way:
B. Crestani (Paris, France). Use of antifibrotics in post-COVID ILD: PRO. Virtual Congress 2021 – Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease?

Member's Comments

No comment yet.

Related content which might interest you: Use of antifibrotics in post-COVID ILD: CON Source: Virtual Congress 2021 – Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease? Year: 2021 PRO recommendation Source: ERS Course 2018 - Noninvasive ventilation: advanced Year: 2018 PRO - Steroids in ARDS Source: Respiratory Failure and Mechanical Ventilation Conference 2020 Year: 2020 PRO: maintenance is cost-effective Source: Annual Congress 2012 - Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC" Year: 2012 PRO - Lung biopsy in ARDS Source: Respiratory Failure and Mechanical Ventilation Conference 2020 Year: 2020 Debate: Antibiotic treatment is contraindicated in acute bronchitis - PRO Source: Annual Congress 2008 - PG1 - EU GRACE network full-day course: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis Year: 2008 Long term application of NIV in COPD - PRO & CON Source: ERS course 2015 Year: 2015 Is there a place for oral mucolytics in the prevention of LRTI? - PRO Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 NIV and pneumonia - PRO & CON Source: ERS course 2015 Year: 2015 The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Inspiration: An assistance program for idiopathic pulmonary fibrosis patients on pirfenidone Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 PRO: Severity scores are useful Source: Annual Congress 2012 - Pro-Con Debate "Severe community-acquired pneumonia: a lung disease?" Year: 2012 Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015